Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

Introduction Lasmiditan is a selective serotonin (5-HT1F) receptor agonist approved in the US for the acute treatment ofmigraine in adults. This phase I, open-label, two-cohort study assessed the pharmacokinetics (PK), safety, and tolerability of lasmiditan in patients with migraine aged 6 to < 1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacokinetics 2021-06, Vol.60 (6), p.819-828
Hauptverfasser:	Tsai, Max, Nery, Emel Serap Monkul, Kerr, Lisa, Khanna, Rashna, Komori, Mika, Dennehy, Ellen B., Wilbraham, Darren, Winner, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adults Benzamides Child Cohort Studies Double-Blind Method Drug dosages Headaches Humans Internal Medicine Laboratories Medicine Medicine & Public Health Migraine Migraine Disorders - drug therapy Original Original Research Article Patients Pediatrics Pharmacokinetics Pharmacology/Toxicology Pharmacotherapy Piperidines Pyridines Serotonin Receptor Agonists Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!